Business
Gilead's Trodelvy becomes first ADC approved for first-line metastatic triple-negative breast cancer in EU
Gilead's sacituzumab govitecan (Trodelvy) has secured European Commission marketing authorization as a first-line monotherapy for metastatic triple-negative...
MoonLake raises USD 150m to commercialize sonelokimab ahead of hidradenitis suppurativa BLA filing
Switzerland-based MoonLake Immunotherapeutics (Nasdaq: MLTX) announced a proposed public offering of USD 150 million in Class A ordinary shares — with...
uniQure raises USD 150m after positive FDA signal on Huntington's disease therapy
Lexington, Massachusetts-based uniQure N.V. (Nasdaq: QURE) announced a proposed underwritten public offering of ordinary shares and pre-funded warrants...
Lilly closes USD 7.8 billion Centessa deal, enters sleep-wake disorder market with OX2R pipeline
The High Court of Justice of England and Wales has sanctioned the scheme of arrangement implementing Eli Lilly's acquisition of Centessa Pharmaceuticals plc...
Bionyra launches with USD 165m to challenge TL1A incumbents in inflammatory disease
France-based Bionyra Pharma, a clinical-stage biopharmaceutical company developing mono and multispecific antibodies for immune-mediated inflammatory...
Nura Bio's USD 73.8m Series B validates SARM1 inhibition strategy in ALS
South San Francisco-based Nura Bio, Inc., a clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, has completed a...
Nuvectis licenses Haisco's late-stage Factor B inhibitor and BRAF program in USD 1.4b deal
Fort Lee, New Jersey-based Nuvectis Pharma, Inc. (Nasdaq: NVCT) has signed an exclusive ex-China license agreement with China-based Haisco Pharmaceutical...
AbbVie adds long-acting IL-13 assets in USD 10.9 billion Apogee acquisition
AbbVie (NYSE: ABBV) has agreed to acquire Apogee Therapeutics (Nasdaq: APGE) in an all-cash transaction valued at approximately USD 10.9 billion, adding a...
Insilico's USD 2.5 billion SK Biopharmaceuticals deal validates AI-first drug discovery at scale
Insilico Medicine (HKEX: 3696) has struck a neuroimmune drug discovery collaboration with South Korea-based SK Biopharmaceuticals (KRX: 326030.KS) worth up...
K2 Therapeutics commits up to USD 980m on masked TCE platform from Antengene
China-based Antengene Corporation Limited (HKEX: 6996) has licensed its preclinical CDH6 × CD3 bispecific T cell engager ATG-106 to K2 Therapeutics, a...
Memento launches with USD 93m to challenge anti-VEGF monopoly in retinal disease
Boston-based Memento Medicines, Inc. has launched with a USD 93 million Series A financing round to advance MMT-205 (previously known as MT-103), a...
Syntax Bio raises USD 14.4m to scale CRISPR-programmed cell therapy for type 1 diabetes
Chicago-based Syntax Bio has closed an expanded Series A totaling USD 14.4 million, bringing total funding to more than USD 25 million, as the synthetic...
SOPHiA Genetics raises USD 57.5 million to expand AI genomics platform beyond oncology
Switzerland-based SOPHiA GENETICS (Nasdaq: SOPH), an AI-native healthcare technology company, announced the closing of an underwritten public offering of...
Portal's mechanoporation platform scales to 100 pharma and academic sites with USD 9 million round
Watertown, Massachusetts-based Portal Biotechnologies, Inc., a cell engineering and drug discovery platform company, has closed an oversubscribed USD 9...
Nortiva Bio launches with USD 5m Gates Foundation grant for long-acting oral contraceptive
Lexington, Massachusetts-based Nortiva Bio, Inc. has launched as a clinical-stage biopharmaceutical company focused on extending the duration of oral...
The AllSci Brief
Systematic R&D and deal news. Daily.